Výsledky vyhledávání - Alain Moussy
- Zobrazuji výsledky 1 - 20 z 21
- Přejít na další stránku
-
1
-
2
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study Autor Patrick Vermersch, R. Benrabah, Nicolás Schmidt, Hélène Zephir, Pierre Clavelou, Cyrille Vongsouthi, Patrice Dubreuil, Alain Moussy, Olivier Hermine
Vydáno 2012Artigo -
3
Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors Autor Sébastien Létard, Ying Yang, Katia Hanssens, Fabienne Palmérini, Phillip S. Leventhal, Stéphanie Guéry, Alain Moussy, Jean‐Pierre Kinet, Olivier Hermine, Patrice Dubreuil
Vydáno 2008Artigo -
4
Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy Autor Daniela Silva Moura, Serge Sultan, Sophie Georgin‐Lavialle, N. Pillet, François Montestruc, Paul Gineste, Stéphane Barète, Gandhi Damaj, Alain Moussy, Olivier Lortholary, Olivier Hermine
Vydáno 2011Artigo -
5
Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model Autor Martine Humbert, Nathalie Castéran, Sébastien Létard, Katia Hanssens, Juan Iovanna, Pascal Finetti, François Bertucci, Thomas Bader, Colin D. Mansfield, Alain Moussy, Olivier Hermine, Patrice Dubreuil
Vydáno 2010Artigo -
6
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial Autor Bruno Dubois, Jesús López‐Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Magda Tsolaki
Vydáno 2023Artigo -
7
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis Autor Jesús S. Mora, Walter G. Bradley, Delia Chaverri, María Hernández-Barral, Javier Mascías, Josep Gámez, Gisella Gargiulo‐Monachelli, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Albert C. Ludolph
Vydáno 2021Artigo -
8
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial Autor F. Piette, Joël Belmin, H. Vincent, Nicolás Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean‐Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine
Vydáno 2011Artigo -
9
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study Autor Jacques Tébib, Xavier Mariette, Pierre Bourgeois, René‐Marc Flipo, Philippe Gaudin, Xavier Le Loët, Paul Gineste, Laurent Guy, Colin D. Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine, Jean Sibilia
Vydáno 2009Artigo -
10
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study Autor C. Paul, B. Sans, Felipe Suárez, Philippe Casassus, Stéphane Barète, Fanny Lanternier, Catherine Grandpeix‐Guyodo, Patrice Dubreuil, Fabienne Palmérini, Colin D. Mansfield, Paul Gineste, Alain Moussy, Olivier Hermine, Olivier Lortholary
Vydáno 2010Artigo -
11
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors Autor K. Hahn, G. Oglivie, Todd Rusk, Patrick Devauchelle, Amy K. LeBlanc, Alfred Μ. Legendre, B.E. Powers, Phillip S. Leventhal, Jean-Pierre Kinet, F. Palmerini, Patrice Dubreuil, Alain Moussy, Olivier Hermine
Vydáno 2008Artigo -
12
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer Autor G. Deplanque, Martin Demarchi, Mohamed Hebbar, Patrick J. Flynn, Bohuslav Melichar, J. Atkins, Elżbieta Nowara, Lem Moyé, David Piquemal, D. Ritter, Patrice Dubreuil, Colin D. Mansfield, Y. Acin, Alain Moussy, Olivier Hermine, Pascal Hammel
Vydáno 2015Artigo -
13
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT Autor Patrice Dubreuil, Sébastien Létard, Marco A. Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S. Leventhal, Colin D. Mansfield, Alain Moussy, Olivier Hermine
Vydáno 2009Artigo -
14
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors Autor Hahn K.A., Legendre A.M., Shaw N.G., Brenda Phillips, Ogilvie G.K., Prescott D.M., Atwater S.W., Carreras J.K., Lana S.E., Tracy A. LaDue, A. Usk, Kinet J.P., Patrice Dubreuil, Alain Moussy, Olivier Hermine
Vydáno 2010Artigo -
15
Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis Autor Olivier Hermine, Olivier Lortholary, Phillip S. Leventhal, Adeline Catteau, Frédérique Soppelsa, Cédric Baude, Annick Cohen-Akenine, Fabienne Palmérini, Katia Hanssens, Ying Yang, Hagay Sobol, Sylvie Fraytag, David Ghez, Felipe Suárez, Stéphane Barète, Philippe Casassus, Sans Beatrice, Michel Arock, Jean Pierre Kinet, Patrice Dubreuil, Alain Moussy
Vydáno 2008Artigo -
16
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial Autor Antoine Adenis, Jean‐Yves Blay, B. Bui-Nguyen, Olivier Bouché, François Bertucci, Nicolás Isambert, Emmanuelle Bompas, L. Chaigneau, Julien Dômont, Isabelle Ray‐Coquard, Aurore Blesius, Brian A. Van Tine, V.R. Bulusu, Patrice Dubreuil, Colin D. Mansfield, Y. Acin, Alain Moussy, Olivier Hermine, Axel Le Cesne
Vydáno 2014Artigo -
17
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial Autor Jesús S. Mora, Angela Genge, Adriano Chió, Conrado J. Estol, Delia Chaverri, Mariluz Hernández, Saúl Marín, Javier Mascías, Gabriel Rodríguez, Mònica Povedano, Andrés Paipa, Raúl Domínguez, Josep Gámez, María Salvadó, Christian Lunetta, Carlos Ballario, Nilo Riva, Jessica Mandrioli, Alain Moussy, Jean‐Pierre Kinet, Christian Auclair, Patrice Dubreuil, Vincent Arnold, Colin D. Mansfield, Olivier Hermine
Vydáno 2019Artigo -
18
Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset Autor Fanny Lanternier, Annick Cohen-Akenine, Fabienne Palmérini, Frédéric Féger, Ying Yang, Yaël Zermati, Stéphane Barète, B. Sans, Cédric Baude, David Ghez, Felipe Suárez, Richard Delarue, Philippe Casassus, Christine Bodemer, Adeline Catteau, Frédérique Soppelsa, Katia Hanssens, Michel Arock, Hagay Sobol, Sylvie Fraïtag, D. Canioni, Alain Moussy, Jean Marie Launay, Patrice Dubreuil, Olivier Hermine, Olivier Lortholary
Vydáno 2008Artigo -
19
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study Autor Olivier Lortholary, Marie‐Olivia Chandesris, C. Bulaï Livideanu, C. Paul, G. Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barète, Srđan Verstovšek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraïtag, Ludovic Lhermitte, S. Georgin Lavialle, Laurent Frenzel, Lawrence B. Afrin, Katia Hanssens, Julie Agopian, Raphaël Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin D. Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
Vydáno 2017Artigo -
20
Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations Autor Christine Bodemer, Olivier Hermine, Fabienne Palmérini, Ying Yang, Catherine Grandpeix‐Guyodo, Phillip S. Leventhal, S. Hadj‐Rabia, Laurent Nasca, Sophie Georgin-Lavialle, Annick Cohen-Akenine, Jean-Marie Launay, Stéphane Barète, Frédéric Féger, Michel Arock, B. Catteau, B. Sans, J.F. Stalder, Francois Skowron, L. Thomas, G Lorette, P. Plantin, Pierre Bordigoni, Olivier Lortholary, Y. De Prost, Alain Moussy, Hagay Sobol, Patrice Dubreuil
Vydáno 2009Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Disease
Oncology
Pathology
Gastroenterology
Alternative medicine
Placebo
Adverse effect
Clinical endpoint
Biology
Cancer
Environmental health
Population
Randomized controlled trial
Systemic mastocytosis
Cancer research
Genetics
Tyrosine-kinase inhibitor
Cohort
Cutaneous Mastocytosis
Immunology
Mast cell
Amyotrophic lateral sclerosis
Confidence interval
Gene
Hazard ratio
Tyrosine kinase
Alzheimer's disease
Chemotherapy